Treatment satisfaction was high.
Participants evidenced high treatment satisfaction, with no adverse events.
Treatment satisfaction was superior with Hizentra.
Treatment satisfaction was high among clients and moderately high among counselors.
The measure was designed along the lines of the widely used Diabetes Treatment Satisfaction Questionnaire (DTSQ) and sister measures of treatment satisfaction for other conditions including diabetic retinopathy.
Fig. 4 Satisfaction with Onabotulinumtoxin A (OBT-A) treatment: a treatment satisfaction of clinicians; b treatment satisfaction of patients (as perceived by clinicians).
Treatment satisfaction was rated on a scale from 0 (no satisfaction) to 10 (highest satisfaction).
Finally, compliance, treatment satisfaction, and potential adverse effects related to tSNS were evaluated.
The MacTSQ is a short measure which investigates a variety of aspects of treatment satisfaction.
Secondary nonheadache measures include medication consumption, psychiatric symptoms, stress and coping, treatment satisfaction and preference, side effects, and others.
Finally, we did not assess treatment satisfaction in the present study.
